Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos Pockets 1.4M Grant for Alzheimer s Research; Seeks Pharma Partner

NEW YORK, Feb. 12 (GenomeWeb News) - Belgian functional genomics company Galapagos Genomics has won a €1.4 million ($1.8 million) grant from a national science institute to perform research into Alzheimer's disease, the company said today.


Specifically, Galapagos will use the money, awarded by the Flemish Institute for the Promotion of Industrial Scientific-Technological Research, to develop an undisclosed number of disease-relevant assays based on neuronal cells.


The company said it intends to use these assays with its adenoviral-based target-discovery platform. Galapagos said its goal is to work with pharma partners to develop any validated drug targets.


Galapagos currently has ongoing R&D collaborations with BayerBoehringer Ingelheim, and Proctor & Gamble.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.